Editorial Material
Cell Biology
Christopher A. Denaro, Yara Haloush, Samuel Y. Hsiao, John J. Orgera, Teresa Osorio, Lindsey M. Riggs, Joshua W. Sassaman, Sarah A. Williams, Anthony R. Monte Carlo, Renata T. Da Costa, Andrey Grigoriev, Maria E. Solesio
Summary: There is a significant lack of knowledge regarding the molecular mechanisms and long-term consequences of SARS-CoV-2 infection in humans, especially its effects on the central nervous system and neurodegenerative disorders.
Article
Nanoscience & Nanotechnology
Zhaoyan Zhao, Yuchen Xiao, Lingqing Xu, Ye Liu, Guanmin Jiang, Wei Wang, Bin Li, Tianchuan Zhu, Qingqin Tan, Lantian Tang, Haibo Zhou, Xi Huang, Hong Shan
Summary: COVID-19 is a worldwide pandemic characterized by massive morbidity and mortality, with uncontrolled inflammatory processes playing a significant role in fatalities. Glycyrrhizic acid nanoparticles show potential for inhibiting viral growth and reducing inflammation, with possible applications in treating COVID-19.
ACS APPLIED MATERIALS & INTERFACES
(2021)
Article
Biochemistry & Molecular Biology
Pankaj Prasun
Summary: COVID-19 is the worst public health crisis of the century, with mitochondria playing an important role in its pathogenesis and affecting the prognosis of patients with obesity, metabolic syndrome, or type 2 diabetes.
DNA AND CELL BIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Nikola Gligorijevic, Mirjana Radomirovic, Olgica Nedic, Marija Stojadinovic, Urmila Khulal, Dragana Stanic-Vucinic, Tanja Cirkovic Velickovic
Summary: The global outbreak of COVID-19 caused by SARS-CoV-2 has led to numerous clinical trials investigating the potential of polyphenols in prevention and treatment, providing a solid basis for developing polyphenol-based natural approaches for preventing and treating COVID-19.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Microbiology
Jakob J. Malin, Isabelle Suarez, Vanessa Priesner, Gerd Fatkenheuer, Jan Rybniker
Summary: Remdesivir is the first approved treatment for COVID-19, showing therapeutic and prophylactic effects in animal models of various viruses. However, it failed in a clinical trial on ebolavirus disease but showed beneficial effects for patients with COVID-19 in a placebo-controlled trial.
CLINICAL MICROBIOLOGY REVIEWS
(2021)
Review
Biology
Manuel Castillejos-Lopez, Luz Maria Torres-Espindola, Juan Carlos Huerta-Cruz, Edgar Flores-Soto, Bianca S. Romero-Martinez, Rafael Velazquez-Cruz, Anjarath Higuera-Iglesias, Angel Camarena, Ana Karen Torres-Soria, Citlaltepetl Salinas-Lara, Rosario Fernandez-Plata, Noe Alvarado-Vasquez, Hector Solis-Chagoyan, Victor Ruiz, Arnoldo Aquino-Galvez
Summary: The SARS-CoV-2 pandemic has confirmed the predictions made by virologists for decades. The challenge faced by the world is to find a treatment, and repurposing drugs is a viable and fast option. However, the mechanisms of action of some drugs are unknown even though they are approved for human use. Therefore, it is ideal, but not necessary, to understand the basic mechanisms of action in order to justify the therapeutic application of a drug to a new disease.
Review
Pharmacology & Pharmacy
Shuangshuang Yang, Shan Shen, Ning Hou
Summary: A review of studies suggests that ivermectin may be effective in treating mild to moderate COVID-19 cases. However, there is no clear evidence or guidelines recommending its use as a therapeutic agent, and caution should be exercised by physicians. Self-medication is not recommended for patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Chemistry, Applied
Poornima P. Vijayan, P. G. Chithra, Pinky Abraham, Jesiya Susan George, Hanna J. Maria, T. Sreedevi, Sabu Thomas
Summary: Nanotechnologists and material scientists are developing sustainable antiviral surface coatings for various substrates to combat the spread of COVID-19, utilizing nanomaterials that interact with the spike protein of SARS-CoV-2. These coatings inhibit viral entry into host cells by depleting the spike glycoprotein, offering important implications for epidemic prevention.
PROGRESS IN ORGANIC COATINGS
(2022)
Article
Microbiology
Muneerah M. Aleissa, Emily A. Silverman, Luisa M. Paredes Acosta, Cameron T. Nutt, Aaron Richterman, Francisco M. Marty
Summary: Remdesivir has been approved for treating hospitalized patients with COVID-19, showing improved survival rates and decreased viral RNA levels when used early in the course of the disease.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Medicine, General & Internal
Anna Olewicz-Gawlik, Barbara Ginter-Matuszewska, Mikolaj Kaminski, Agnieszka Adamek, Maciej Bura, Iwona Mozer-Lisewska, Arleta Kowala-Piaskowska
Summary: The study aimed to describe the clinical outcomes and changes in inflammatory markers in Polish patients treated with tocilizumab. The results showed that patients who died had higher levels of IL-6 and LDH compared to survivors, and further increase in LDH and IL-6 after administration of tocilizumab was a prognostic factor for unfavorable outcomes.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Christopher Hopkins, Chidinma Onweni, Victoria Zambito, DeLisa Fairweather, Kathryn McCormick, Hideki Ebihara, Thomas Caulfield, Yu Shrike Zhang, W. David Freeman
Summary: This perspective article emphasizes the importance of combination therapies in battling the severity of complications from SARS-CoV-2 infection, proposing different systems for fast and efficient combinatorial assessment of therapeutic candidates.
JOURNAL OF MOLECULAR BIOLOGY
(2021)
Review
Virology
Zheng Yao Low, Ashley Jia Wen Yip, Vincent T. K. Chow, Sunil K. Lal
Summary: The family of Suppressor of Cytokine Signalling (SOCS) proteins plays crucial roles in virus-host interactions, with viruses exploiting them to dampen host antiviral responses and enhance viral replication. Research into SOCS protein inhibitors as potential therapeutics for COVID-19 shows promise in exploring new treatment options.
REVIEWS IN MEDICAL VIROLOGY
(2022)
Review
Pharmacology & Pharmacy
Miguel Angel Martinez
Summary: This article discusses whether drug repurposing is the best strategy for developing effective therapies to treat COVID-19 and other viral human infections.
DRUG DISCOVERY TODAY
(2022)
Review
Medicine, General & Internal
Dan H. Barouch
Summary: This article reviews the protective effects of vaccination and prior infection on severe Covid-19, and proposes future research directions.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Qin Liu, Qi Su, Fen Zhang, Hein M. Tun, Joyce Wing Yan Mak, Grace Chung-Yan Lui, Susanna So Shan Ng, Jessica Y. L. Ching, Amy Li, Wenqi Lu, Chenyu Liu, Chun Pan Cheung, David S. C. Hui, Paul K. S. Chan, Francis Ka Leung Chan, Siew C. Ng
Summary: By integrating clinical features and multi-omics data, the authors identified specific gut microbiome patterns associated with disease severity and development of post-acute COVID-19 syndrome. These findings highlight the potential utility of host phenotype and multi-kingdom microbiota profiling as a prognostic tool for patients with COVID-19.
NATURE COMMUNICATIONS
(2022)
Review
Pharmacology & Pharmacy
Srijan Dubey, Sayak Ghosh, Debosmita Goswami, Debapriya Ghatak, Rudranil De
Summary: Macrophages are immune cells that can engulf and destroy target cells, including tumor cells. Some macrophages undergo a change to become polarized M2 macrophages while devouring cancer cells. M2 macrophages play important roles in metastasis, tumor suppression, and angiogenesis.
BIOCHEMICAL PHARMACOLOGY
(2023)